Enanta Pharmaceuticals IncENTA
Price (close)
$12.00
Market cap
$349.4M
P/E
—
Revenue (TTM)
$65.3M
Net income
-$63.2M
Dividend yield
—
1-year total return
54.8%
Net margin
-96.9%
Revenue growth
0.7%
Debt / equity
—
What Enanta Pharmaceuticals Inc does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Net income | -$36.2M | -$79.0M | -$121.8M | -$133.8M | -$116.0M | -$81.9M |
| Free cash flow | $5.6M | -$70.7M | -$86.9M | -$112.2M | -$96.7M | -$32.2M |
More on ENTA.
- Enanta Pharmaceuticals Inc summary
- Enanta Pharmaceuticals Inc financial statements
- Enanta Pharmaceuticals Inc key metrics
- Enanta Pharmaceuticals Inc health scores and style box
- Enanta Pharmaceuticals Inc earnings
- Enanta Pharmaceuticals Inc dividends
- Enanta Pharmaceuticals Inc valuation
- Enanta Pharmaceuticals Inc ownership and insiders
- Enanta Pharmaceuticals Inc peers
Figures from Enanta Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.